The United Kingdom and the United States have concluded a landmark trade agreement that will maintain no tariffs on British medicine exports being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that duties on these key exports will be held at zero for a period of the next three years.
This development follows previous warnings to dramatically increase import taxes on patented drug imports, with increases floated as high as one hundred percent.
"This arrangement with the UK bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to transatlantic medicine commerce," a release noted.
Trade Importance
Medicines are one of the Britain's biggest export categories to the US, which is by far the primary destination for major British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of the third quarter, the UK shipped pharmaceutical products worth billions to the US. This value made up a significant portion of all goods exports in that timeframe.
"This guarantee secures jobs, increases investment and paves the way for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key British Pledges
The pact involves several specific commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to double overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments topped 20%.
Recent Tensions
The deal comes amid a protracted tension between the sector and the British authorities over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that American customers were charged significantly more for the identical medicines than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been delayed or cancelled, while major investments have been announced toward projects in the United States.
A senior figure stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its total funding over the past decade.
